drug

IBZM-SPECT (bolus and constant infusion paradigm)

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
PROCEDURE
Pre-approval / investigational in the US
Developed by Ludwig-Maximilians - University of Munich
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
PROCEDURE

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

1
Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects
NCT00166322—Completed

KOLs & investigators

2
Klaus Tatsch, MD
Oliver Pogarell, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Ludwig-Maximilians - University of Munich
company
trial
Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects
NA
trial
indication
Schizophrenia
indication
Schizophrenia
indication
KOL
Klaus Tatsch, MD
KOL score —
person
Oliver Pogarell, MD
KOL score —
person